Fuller & Thaler Asset Management Inc. Has $93.73 Million Position in Integer Holdings Corporation $ITGR

Key Points

• Fuller & Thaler Asset Management Inc. reduced its holdings in Integer Holdings Corporation by 18.7%, now owning approximately 2.28% of the company, valued at $93,732,000.
• Recent analyst reports reflect mixed sentiments for Integer, with price targets adjusted down by firms like Raymond James and Truist Financial, while others like Citigroup upgraded the stock to a "strong-buy".
• Integer reported a quarterly revenue of $476 million, surpassing analysts' expectations, but reported an EPS of $1.55, missing consensus estimates by $0.02.

Fuller & Thaler Asset Management Inc. reduced its holdings in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 18.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 794,274 shares of the medical equipment provider's stock after selling 182,898 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 2.28% of Integer worth $93,732,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Opal Wealth Advisors LLC bought a new stake in shares of Integer in the first quarter valued at about $28,000. AdvisorNet Financial Inc bought a new stake in shares of Integer in the first quarter valued at about $28,000. Bessemer Group Inc. lifted its stake in shares of Integer by 73.1% in the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 125 shares during the period. Sterling Capital Management LLC lifted its stake in shares of Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 279 shares during the period. Finally, Headlands Technologies LLC lifted its stake in shares of Integer by 1,234.8% in the first quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock valued at $145,000 after buying an additional 1,136 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Price Performance

Shares of NYSE ITGR traded up $3.8190 during mid-day trading on Friday, hitting $110.6490. 256,433 shares of the stock were exchanged, compared to its average volume of 479,861. The company has a market cap of $3.88 billion, a P/E ratio of 48.74, a PEG ratio of 0.85 and a beta of 1.02. The stock's fifty day simple moving average is $113.91 and its two-hundred day simple moving average is $119.40. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. Integer Holdings Corporation has a twelve month low of $104.93 and a twelve month high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). The firm had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. Integer had a return on equity of 12.27% and a net margin of 4.61%.The business's quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, analysts forecast that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ITGR shares. Benchmark reduced their target price on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research note on Friday, April 25th. Wall Street Zen upgraded shares of Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. Raymond James Financial reduced their target price on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research note on Friday, July 25th. Wells Fargo & Company cut their price target on shares of Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Finally, Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and raised their price target for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $140.25.

Insider Activity at Integer

In other news, Director Donald J. Spence sold 14,739 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the sale, the director owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. This trade represents a 43.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Martin C. Maxwell sold 8,720 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the sale, the director directly owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. The trade was a 28.23% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.16% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.